AstraZeneca
Cambridge ,
Cambridgeshire CB2 0AA
United Kingdom
- Home
- Companies
- AstraZeneca
- Products
- Model AZD5055 - Phase I - Idiopathic ...
Model AZD5055 - Phase I - Idiopathic Pulmonary Fibrosis
Mechanism: Porcupine inhibitor. Area under investigation: idiopathic pulmonary fibrosis. Date commenced phase: Q4 2021. Estimated Filing Acceptance: Country US: EU: Japan: China. Additional information: Molecule size: Small molecule. Status change:
-
Most popular related searches
Customer reviews
No reviews were found for Model AZD5055 - Phase I - Idiopathic Pulmonary Fibrosis. Be the first to review!